• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    2/27/24 8:06:18 AM ET
    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BEAT alert in real time by email

    Gainers

    • Janux Therapeutics (NASDAQ:JANX) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion.
    • Viking Therapeutics (NASDAQ:VKTX) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion.
    • TransMedics Gr (NASDAQ:TMDX) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday.
    • Codexis (NASDAQ:CDXS) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million.
    • Ligand Pharmaceuticals (NASDAQ:LGND) shares moved upwards by 20.93% to $90.0. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today.
    • Hims & Hers Health (NYSE:HIMS) shares rose 19.5% to $12.25. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out yesterday.

    Losers

    • NRX Pharmaceuticals (NASDAQ:NRXP) shares decreased by 22.9% to $0.33 during Tuesday's pre-market session. The company's market cap stands at $28.0 million.
    • Veradigm (NASDAQ:MDRX) shares decreased by 22.03% to $6.48. The market value of their outstanding shares is at $708.0 million.
    • Precision BioSciences (NASDAQ:DTIL) shares decreased by 18.32% to $13.07. The market value of their outstanding shares is at $53.1 million.
    • HeartBeam (NASDAQ:BEAT) shares fell 14.79% to $1.21. The market value of their outstanding shares is at $31.8 million.
    • MediciNova (NASDAQ:MNOV) shares fell 11.54% to $1.15. The company's market cap stands at $56.4 million.
    • BioSig Technologies (NASDAQ:BSGM) stock fell 10.23% to $0.43. The market value of their outstanding shares is at $4.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT
    $BSGM
    $CDXS
    $DTIL

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    3/31/2026$4.00Buy
    B. Riley Securities
    Heartbeam Inc.
    $BEAT
    3/27/2026$5.00Buy
    D. Boral Capital
    Viking Therapeutics Inc.
    $VKTX
    3/26/2026Peer Perform
    Wolfe Research
    Heartbeam Inc.
    $BEAT
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    Medicinova Inc
    $MNOV
    3/16/2026$10.00Buy
    H.C. Wainwright
    Ligand Pharmaceuticals Incorporated
    $LGND
    3/11/2026$244.00Buy
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux. "This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnersh

    4/1/26 8:01:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    How Decentralized AI is Unlocking Value in Cardiac Diagnostics

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /CNW/ -- USANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European Union over €282 billion annually while tragically claiming 1.7 million lives a year[1]. This immense structural pressure is acting as a catalyst for smart money, with institutional capital rapidly accumulating positions in scalable, AI-enabled diagnostic platforms. In fact, peer-reviewed data now confirms that AI-driven healthcare startups command the largest share of venture funding in the entire biopharmaceutical sector[2]. At the center of this pivotal transit

    3/27/26 9:30:00 AM ET
    $BEAT
    $GEHC
    $HTFL
    Medical/Dental Instruments
    Health Care
    Medical Electronics
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Germano Geno J bought $14,160 worth of shares (3,000 units at $4.72), increasing direct ownership by 14% to 23,883 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:02:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frankel Stanley bought $12,690 worth of shares (2,700 units at $4.70), increasing direct ownership by 16% to 19,478 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:01:09 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Brown Melinda bought $6,864 worth of shares (1,381 units at $4.97), increasing direct ownership by 6% to 23,346 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:00:53 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kozarich John W

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    4/2/26 7:43:34 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Reardon Andrew

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    4/2/26 6:56:59 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lamattina John L

    4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

    3/31/26 5:53:19 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on HeartBeam with a new price target

    B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    3/31/26 8:12:24 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on HeartBeam with a new price target

    D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00

    3/27/26 8:50:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Viking Therapeutics

    Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    SEC Filings

    View All

    SEC Form DEFA14A filed by Viking Therapeutics Inc.

    DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)

    4/1/26 4:15:28 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Viking Therapeutics Inc.

    DEF 14A - Viking Therapeutics, Inc. (0001607678) (Filer)

    4/1/26 4:14:56 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ligand Pharmaceuticals Incorporated

    144 - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

    4/1/26 4:10:39 PM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Leadership Updates

    Live Leadership Updates

    View All

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

    Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth. As of December 31, 2025, all previously issued convertible debt had been converted into common stock.Anticipated FDA approval of at least one new drug – Preservative Free Ketamine under an ANDA—during Q3 2026. A favorable preliminary bioequivalence determination was received from the FDA last week.A Type C in-person meeting wi

    3/24/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

    WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

    3/19/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    $BSGM
    $CDXS
    $DTIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

    SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

    11/14/24 4:50:29 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:24:38 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care